Whilst for the NF-κB pathway, CYLD and TRAF3 mutations appear to occur at a similar high rate in both cancers (8–11% rates), followed by the same rate of mutations of NLRC5 (6% rates) (Table 3). This evidence concerns the gene CYLD and cancer.